Troponin mutations in cardiomyopathies

Advances in Experimental Medicine and Biology

Volumn 592, Issue , 2007, Pages 201-226

  Mogensen, Jens ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CONTRACTILE PROTEIN; TROPONIN C; TROPONIN I; TROPONIN T;

AMINO ACID SUBSTITUTION; CLINICAL FEATURE; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; GENE MUTATION; GENETIC DISORDER; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RESTRICTIVE CARDIOMYOPATHY; SUDDEN DEATH;

EID: 84934439239     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-4-431-38453-3_18     Document Type: Conference Paper

References (108)

1. P. Richardson, W. McKenna, M. Bristow, B. Maisch, B. Mautner, J. O'Connell, E. Olsen, G. Thiene, J. Goodwin, I. Gyarfas, I. Martin, and P. Nordet, Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies, Circulation 93, 841-842 (1996).
2. P. Richard, P. Charron, L. Carrier, C. Ledeuil, T. Cheav, C. Pichereau, A. Benaiche, R. Isnard, O. Dubourg, M. Burban, J. P. Gueffet, A. Millaire, M. Desnos, K. Schwartz, B. Hainque, and M. Komajda, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation 107(17), 2227-2232.
3. L. Mestroni, C. Rocco, D. Gregori, G. Sinagra, L. A. Di, S. Miocic, M. Vatta, B. Pinamonti, F. Muntoni, A. L. Caforio, W. J. Mckenna, A. Falaschi, and M. Giacca, Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group, J. Am. Coll. Cardiol. 34, 181-190 (1897).
4. M. S. Hamid, M. Norman, A. Quraishi, S. Firoozi, R. Thaman, J. R. Gimeno, B. Sachdev, E. Rowland, P. M. Elliott, and W. J. McKenna, Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria, J. Am. Coll. Cardiol. 40, 1445-1450 (2002).
5. B. J. Maron, J. M. Gardin, J. M. Flack, S. S. Gidding, T. T. Kurosaki, and D. E. Bild, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults, Circulation 92, 785-789 (1995).
6. B. J. Maron, J. S. Gottdiener, and S. E. Epstein, Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients, Am. J. Cardiol. 48, 418-428 (1981).
7. H. G. Klues, A. Schiffers, and B. J. Maron, Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients, J. Am. Coll. Cardiol. 26, 1699-1708 (1995).
8. B. J. Maron, R. O. Bonow, R. O. Cannon 3rd, M. B. Leon, and S. E. Epstein, Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2), N. Engl. J. Med. 316, 844-852 (1987).
9. P. Spirito, and B. J. Maron, Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography, Am. J. Cardiol. 54, 1039-1046 (1984).
10. B. J. Maron, P. Spirito, Y. Wesley, and J. Arce, Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy, N. Engl. J. Med. 315, 610-614 (1986).
11. H. Niimura, L. L. Bachinski, S. Sangwatanaroj, H. Watkins, A. E. Chudley, W. McKenna, A. Kristinsson, R. Roberts, M. Sole, B. J. Maron, J. G. Seidman, and C. E. Seidman, Mutations in the gene for cardiac myosin-binding protein C and late- onset familial hypertrophic cardiomyopathy [see comments], N. Engl. J. Med. 338, 1248-1257 (1998).
12. J. Mogensen, R. T. Murphy, T. Kubo, A. Bahl, J. C. Moon, I. C. Klausen, P. M. Elliott, and W. J. McKenna, Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy, J. Am. Coll. Cardiol. 44, 2315-2325 (2004).
13. P. M. Elliott, J. Poloniecki, S. Dickie, S. Sharma, L. Monserrat, A. Varnava, N. G. Mahon, and W. J. McKenna, Sudden death in hypertrophic cardiomyopathy: identifi cation of high risk patients, J. Am. Coll. Cardiol. 36(7), 2212-2218 (2000).
14. B. J. Maron, J. Shirani, L. C. Poliac, R. Mathenge, W. C. Roberts, and F. O. Mueller, Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles [see comments], JAMA 276, 199-204 (1996).
15. B. J. Maron, W. K. Shen, M. S. Link, A. E. Epstein, A. K. Almquist, J. P. Daubert, G. H. Bardy, S. Favale, R. F. Rea, G. Boriani, N. A. Estes, and P. Spirito, Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N. Engl. J. Med. 342(6), 365-373 (2000).
16. P. M. Elliott, S. Sharma, A. Varnava, J. Poloniecki, E. Rowland, and W. J. McKenna, Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy, J. Am. Coll. Cardiol. 33, 1596-1601 (1999).
17. B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. TenCate, E. D. Wigle, R. A. Vogel, J. Abrams, E. R. Bates, B. R. Brodie, P. G. Danias, G. Gregoratos, M. A. Hlatky, J. S. Hochman, S. Kaul, R. C. Lichtenberg, J. R. Lindner, R. A. O'Rourke, G. M. Pohost, R. S. Schofield, C. M. Tracy, W. L. Winters, Jr., W. W. Klein, S. G. Priori, A. Alonso-Garcia, C. Blimstrom-Lundqvist, G. De Backer, J. Deckers, M. Flather, J. Hradec, A. Oto, A. Parkhomenko, S. Silber, and A. Torbicki, American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, Eur. Heart J. 24, 1965-1991 (2003).
18. A. A. Geisterfer-Lowrance, S. Kass, G. Tanigawa, H. P. Vosberg, W. McKenna, C. E. Seidman, and J. G. Seidman, A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation, Cell 62, 999-1006 (1990).
19. L. Thierfelder, H. Watkins, C. MacRae, R. Lamas, W. McKenna, H. P. Vosberg, J. G. Seidman, and C. E. Seidman, Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere, Cell 77, 701-712 (1994).
20. G. Bonne, L. Carrier, J. Bercovici, C. Cruaud, P. Richard, B. Hainque, M. Gautel, S. Labeit, M. James, J. Beckmann, J. Weissenbach, H. P. Vosberg, M. Fiszman, M. Komajda, and K. Schwartz, Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy, Nat. Genet. 11, 438-440 (1995).
21. H. Watkins, D. Conner, L. Thierfelder, J. A. Jarcho, C. MacRae, W. J. McKenna, B. J. Maron, J. G. Seidman, and C. E. Seidman, Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy, Nat. Genet. 11, 434-437 (1995).
22. K. Poetter, H. Jiang, S. Hassanzadeh, S. R. Master, A. Chang, M. C. Dalakas, I. Rayment, J. R. Sellers, L. Fananapazir, and N. D. Epstein, Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle, Nat. Genet. 13, 63-69 (1996).
23. A. Kimura, H. Harada, J. E. Park, H. Nishi, M. Satoh, M. Takahashi, S. Hiroi, T. Sasaoka, N. Ohbuchi, T. Nakamura, T. Koyanagi, T. H. Hwang, J. A. Choo, K. S. Chung, A. Hasegawa, R. Nagai, O. Okazaki, H. Nakamura, M. Matsuzaki, T. Sakamoto, H. Toshima, Y. Koga, T. Imaizumi, and T. Sasazuki, Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyo-pathy, Nat. Genet. 16, 379-382 (1997).
24. B. Hoffmann, H. Schmidt-Traub, A. Perrot, K. J. Osterziel, and R. Gessner, First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy, Hum. Mutat. 17(6), 524 (2001).
25. M. Satoh, M. Takahashi, T. Sakamoto, M. Hiroe, F. Marumo, and A. Kimura, Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene, Biochem. Biophys. Res. Commun. 262, 411-417 (1999).
26. H. Niimura, K. K. Patton, W. J. McKenna, J. Soults, B. J. Maron, J. G. Seidman, and C. E. Seidman, Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly, Circulation 105(4), 446-451 (2002).
27. C. Geier, A. Perrot, C. Ozcelik, P. Binner, D. Counsell, K. Hoffmann, B. Pilz, Y. Martiniak, K. Gehmlich, P. F. van der Ven, D. O. Furst, A. Vornwald, E. von Hodenberg, P. Nurnberg, T. Scheffold, R. Dietz, and K. J. Osterziel, Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy, Circulation 107(10), 1390-1395 (2003).
28. A. Keren, and R. L. Popp, Assignment of patients into the classification of cardiomyopathies, Circulation 86, 1622-1633 (1992).
29. A. Angelini, V. Calzolari, G. Thiene, G. M. Boffa, M. Valente, L. Daliento, C. Basso, F. Calabrese, R. Razzolini, U. Livi, and R. Chioin, Morphologic spectrum of primary restrictive cardiomyopathy, Am. J. Cardiol. 80, 1046-1050 (1997).
30. M. J. Saraiva, Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies, Expert Rev. Mol. Med. 2002, 1-11 (2002).
31. J. A. Towbin, and N. E. Bowles, The failing heart, Nature 415(6868), 227-233 (2002).
32. L. Mestroni, B. Maisch, W. J. McKenna, K. Schwartz, P. Charron, C. Rocco, F. Tesson, A. Richter, A. Wilke, and M. Komajda, Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy, Eur. Heart J. 20, 93-102 (1999).
33. M. B. Codd, D. D. Sugrue, B. J. Gersh, and L. J. Melton, Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 80, 564-572 (1989).
34. J. N. Cohn, M. R. Bristow, K. R. Chien, W. S. Colucci, O. H. Frazier, L. A. Leinwand, B. H. Lorell, A. J. Moss, E. H. Sonnenblick, R. A. Walsh, S. C. Mockrin, and L. Reinlib, Report of the national heart, lung, and blood institute special emphasis panel on heart failure research, Circulation 95, 766-770 (1997).
35. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors, N. Engl. J. Med. 327, 685-691 (1992).
36. M. A. Pfeffer, E. Braunwald, L. A. Moye, L. Basta, E. J. J. Brown, T. E. Cuddy, B. R. Davis, E. M. Geltman, S. Goldman, and G. C. Flaker, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators, N. Engl. J. Med. 327, 669-677 (1992).
37. F. Waagstein, M. R. Bristow, K. Swedberg, F. Camerini, M. B. Fowler, M. A. Silver, E. M. Gilbert, M. R. Johnson, F. G. Goss, and A. Hjalmarson, Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, Lancet 342, 1441-1446 (1993).
38. P. A. Poole-Wilson, K. Swedberg, J. G. Cleland, L. A. Di, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W. J. Remme, C. Torp-Pedersen, A. Scherhag, and A. Skene, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet 362(9377), 7-13 (2003).
39. J. G. Cleland, D. J. Pennell, S. G. Ray, A. J. Coats, P. W. Macfarlane, G. D. Murray, J. D. Mule, Z. Vered, and A. Lahiri, Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial, Lancet 362(9377), 14-21 (2003).
40. S. G. Molhoek, J. J. Bax, L. van Erven, M. Bootsma, E. Boersma, P. Steendijk, E. E. Van der Wall, and M. J. Schalij, Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy, Am. J. Cardiol. 93, 860-863 (2004).
41. P. T. Mortensen, P. Sogaard, H. Mansour, J. Ponsonaille, D. Gras, A. Lazarus, W. Reiser, C. Alonso, C. M. Linde, M. Lunati, B. Kramm, and E. M. Harrison, Sequential biventricular pacing: evaluation of safety and efficacy, Pacing Clin. Electrophysiol. 27, 339-345 (2004).
42. J. J. Blanc, V. Bertault-Valls, M. Fatemi, M. Gilard, P. Y. Pennec, and Y. Etienne, Midterm benefits of left univentricular pacing in patients with congestive heart failure, Circulation 109, 1741-1744 (2004).
43. A. Auricchio, C. Stellbrink, C. Butter, S. Sack, J. Vogt, A. R. Misier, D. Bocker, M. Block, J. H. Kirkels, A. Kramer, and E. Huvelle, Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay, J. Am. Coll. Cardiol. 42, 2109-2116 (2003).
44. J. G. Seidman, and C. Seidman, The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms, Cell 104(4), 557-567 (2001).
45. R. T. Murphy, J. Mogensen, A. Shaw, T. Kubo, S. Hughes, and W. J. McKenna, Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy, Lancet 363, 371-372 (2004).
46. J. Mogensen, R. T. Murphy, T. Shaw, A. Bahl, C. Redwood, H. Watkins, M. Burke, P. M. Elliott, and W. J. McKenna, Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy, J. Am. Coll. Cardiol. 44, 2033-2040 (2004).
47. T. M. Olson, V. V. Michels, S. N. Thibodeau, Y. S. Tai, and M. T. Keating, Actin mutations in dilated cardiomyopathy, a heritable form of heart failure, Science 280, 750-752 (1998).
48. T. M. Olson, N. Y. Kishimoto, F. G. Whitby, and V. V. Michels, Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy, J. Mol. Cell Cardiol. 33(4), 723-732 (2001).
49. M. Kamisago, S. D. Sharma, S. R. DePalma, S. Solomon, P. Sharma, B. McDonough, L. Smoot, M. P. Mullen, P. K. Woolf, E. D. Wigle, J. G. Seidman, and C. E. Seidman, Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy, N. Engl. J. Med. 343(23), 1688-1696 (2000).
50. B. Gerull, M. Gramlich, J. Atherton, M. McNabb, K. Trombitas, S. Sasse-Klaassen, J. G. Seidman, C. Seidman, H. Granzier, S. Labeit, M. Frenneaux, and L. Thierfelder, Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy, Nat. Genet. 30(2), 201-204 (2002).
51. M. Itoh-Satoh, T. Hayashi, H. Nishi, Y. Koga, T. Arimura, T. Koyanagi, M. Takahashi, S. Hohda, K. Ueda, T. Nouchi, M. Hiroe, F. Marumo, T. Imaizumi, M. Yasunami, and A. Kimura, Titin mutations as the molecular basis for dilated cardiomyopathy, Biochem. Biophys. Res. Commun. 291, 385-393 (2002).
52. S. Daehmlow, J. Erdmann, T. Knueppel, C. Gille, C. Froemmel, M. Hummel, R. Hetzer, and V. Regitz-Zagrosek, Novel mutations in sarcomeric protein genes in dilated cardiomyopathy, Biochem. Biophys. Res. Commun. 298(1), 116-120 (2002).
53. R. Knoll, M. Hoshijima, H. M. Hoffman, V. Person, I. Lorenzen-Schmidt, M. L. Bang, T. Hayashi, N. Shiga, H. Yasukawa, W. Schaper, W. McKenna, M. Yokoyama, N. J. Schork, J. H. Omens, A. D. McCulloch, A. Kimura, C. C. Gregorio, W. Poller, J. Schaper, H. P. Schultheiss, and K. R. Chien, The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy, Cell 111(7), 943-955 (2002).
54. D. Fatkin, C. MacRae, T. Sasaki, M. R. Wolff, M. Porcu, M. Frenneaux, J. Atherton, H. J. J. Vidaillet, S. Spudich, G. U. De, et al., Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease, N. Engl. J. Med. 341, 1715-1724 (1897).
55. S. Bione, E. Maestrini, S. Rivella, M. Mancini, S. Regis, G. Romeo, and D. Toniolo, Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy, Nat. Genet. 8, 323-327 (1994).
56. D. Li, T. Tapscoft, O. Gonzalez, P. E. Burch, M. A. Quinones, W. A. Zoghbi, R. Hill, L. L. Bachinski, D. L. Mann, and R. Roberts, Desmin mutation responsible for idiopathic dilated cardiomyopathy, Circulation 100, 461-464 (1897).
57. S. Tsubata, K. R. Bowles, M. Vatta, C. Zintz, J. Titus, L. Muhonen, N. E. Bowles, and J. A. Towbin, Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy, J. Clin. Invest. 106(5), 655-662 (2000).
58. F. Muntoni, M. Cau, A. Ganau, R. Congiu, G. Arvedi, A. Mateddu, M. G. Marrosu, C. Cianchetti, G. Realdi, and A. Cao, Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy, N. Engl. J. Med. 329, 921-925 (1993).
59. E. E. Norgett, S. J. Hatsell, L. Carvajal-Huerta, J. C. Cabezas, J. Common, P. E. Purkis, N. Whittock, I. M. Leigh, H. P. Stevens, and D. P. Kelsell, Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma, Hum. Mol. Genet. 9, 2761-2766 (2000).
60. T. M. Olson, S. Illenberger, N. Y. Kishimoto, S. Huttelmaier, M. T. Keating, and B. M. Jockusch, Metavinculin mutations alter actin interaction in dilated cardiomyopathy, Circulation 105(4), 431-437 (2002).
61. B. Mohapatra, S. Jimenez, J. H. Lin, K. R. Bowles, K. J. Coveler, J. G. Marx, M. A. Chrisco, R. T. Murphy, P. R. Lurie, R. J. Schwartz, P. M. Elliott, M. Vatta, W. McKenna, J. A. Towbin, and N. E. Bowles, Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis, Mol. Genet. Metab. 80, 207-215 (2003).
62. M. Vatta, B. Mohapatra, S. Jimenez, X. Sanchez, G. Faulkner, Z. Perles, G. Sinagra, J. H. Lin, T. M. Vu, Q. Zhou, K. R. Bowles, A. Di Lenarda, L. Schimmenti, M. Fox, M. A. Chrisco, R. T. Murphy, W. McKenna, P. Elliott, N. E. Bowles, J. Chen, G. Valle, and J. A. Towbin, Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction, J. Am. Coll. Cardiol. 42, 2014-2027 (2003).
63. J. P. Schmitt, M. Kamisago, M. Asahi, G. H. Li, F. Ahmad, U. Mende, E. G. Kranias, D. H. MacLennan, J. G. Seidman, and C. E. Seidman, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science 299(5611), 1410-1413 (2003).
64. M. Bienengraeber, T. M. Olson, V. A. Selivanov, E. C. Kathmann, F. O'Cochlain, F. Gao, A. B. Karger, J. D. Ballew, D. M. Hodgson, L. V. Zingman, Y. P. Pang, A. E. Alekseev, and A. Terzic, ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating, Nat. Genet. 36, 382-387 (2004).
65. F. Ichida, S. Tsubata, K. R. Bowles, N. Haneda, K. Uese, T. Miyawaki, W. J. Dreyer, J. Messina, H. Li, N. E. Bowles, and J. A. Towbin, Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome, Circulation 103(9), 1256-1263 (2001).
66. R. Chen, T. Tsuji, F. Ichida, K. R. Bowles, X. Yu, S. Watanabe, K. Hirono, S. Tsubata, Y. Hamamichi, J. Ohta, Y. Imai, N. E. Bowles, T. Miyawaki, and J. A. Towbin, Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction, Mol. Genet. Metab. 77(4), 319-325 (2002).
67. A. Suomalainen, A. Paetau, H. Leinonen, A. Majander, L. Peltonen, and H. Somer, Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA, Lancet 340, 1319-1320 (1992).
68. H. Watkins, A. Rosenzweig, D. S. Hwang, T. Levi, W. McKenna, C. E. Seidman, and J. G. Seidman, Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy, N. Engl. J. Med. 326, 1108-1114 (1992).
69. H. Watkins, W. J. McKenna, L. Thierfelder, H. J. Suk, R. Anan, A. O'Donoghue, P. Spirito, A. Matsumori, C. S. Moravec, C. Seidman, and J. G. Seidman, Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy, N. Engl. J. Med. 332, 1058-1064 (1995).
70. A. Kumar, K. Crawford, L. Close, M. Madison, J. Lorenz, T. Doetschman, S. Pawlowski, J. Duffy, J. Neumann, J. Robbins, G. P. Boivin, B. A. O'Toole, and J. L. Lessard, Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin, Proc. Natl. Acad. Sci. USA 94, 4406-4411 (1997).
71. J. James, Y. Zhang, H. Osinska, A. Sanbe, R. Klevitsky, T. E. Hewett, and J. Robbins, Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy, Circ. Res. 87(9), 805-811 (2000).
72. M. Muthuchamy, K. Pieples, P. Rethinasamy, B. Hoit, I. L. Grupp, G. P. Boivin, B. Wolska, C. Evans, R. J. Solaro, and D. F. Wieczorek, Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha- tropomyosin manifests cardiac dysfunction, Circ. Res. 85, 47-56 (1999).
73. D. Burton, H. Abdulrazzak, A. Knott, K. Elliott, C. Redwood, H. Watkins, S. Marston, and C. Ashley, Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility, Biochem. J. 362(Pt2), 443-451 (2002).
74. K. Elliott, H. Watkins, and C. S. Redwood, Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy, J. Biol. Chem. 275(29), 22069-22074 (2000).
75. A. Hinkle, and L. S. Tobacman, Folding and function of the troponin tail domain. Effects of cardiomyopathic troponin T mutations, J. Biol. Chem. 278, 506-513 (2003).
76. R. Lang, A. V. Gomes, J. Zhao, P. R. Housmans, T. Miller, and J. D. Potter, Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy, J. Biol. Chem. 277(14), 11670-11678 (2002).
77. S. Morimoto, Q. W. Lu, K. Harada, F. Takahashi-Yanaga, R. Minakami, M. Ohta, T. Sasaguri, and I. Ohtsuki, Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy, Proc. Natl. Acad. Sci. USA 99(2), 913-918 (2002).
78. Y. Nakamura, H. Suzuki, M. Sakaguchi, and K. Mihara, Targeting and assembly of rat mitochondrial translocase of outer membrane 22 (TOM22) into the TOM complex, J. Biol. Chem. 279, 21223-21232 (2004).
79. C. Y. Hong, J. H. Park, R. S. Ahn, S. Y. Im, H. S. Choi, J. Soh, S. H. Mellon, and K. Lee, Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha, Mol. Cell. Biol. 24, 2593-2604 (2004).
80. A. A. Hagege, O. Dubourg, M. Desnos, R. Mirochnik, G. Isnard, G. Bonne, L. Carrier, P. Guicheney, J. B. Bouhour, K. Schwartz, and M. Komajda, Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy, Eur. Heart J. 19, 490-499 (1998).
81. J. Mogensen, I. C. Klausen, A. K. Pedersen, H. Egeblad, P. Bross, T. A. Kruse, N. Gregersen, P. S. Hansen, U. Baandrup, and A. D. Borglum, Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy, J. Clin. Invest. 103, R39-R43 (1999).
82. P. Charron, O. Dubourg, M. Desnos, R. Isnard, A. Hagege, A. Millaire, L. Carrier, G. Bonne, F. Tesson, P. Richard, J. B. Bouhour, K. Schwartz, and M. Komajda, Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population, Circulation 96, 214-219 (1997).
83. L. Thierfelder, C. MacRae, H. Watkins, J. Tomfohrde, M. Williams, W. McKenna, K. Bohm, G. Noeske, M. Schlepper, A. Bowcock, H. Vosberg, J. G. Seidman, and C. Seidman, A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2, Proc. Natl. Acad. Sci. USA 90, 6270-6274 (1993).
84. H. Watkins, C. MacRae, L. Thierfelder, Y. H. Chou, M. Frenneaux, W. McKenna, J. G. Seidman, and C. E. Seidman, A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3, Nat. Genet. 3, 333-337 (1993).
85. W. J. McKenna, P. Spirito, M. Desnos, O. Dubourg, and M. Komajda, Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families, Heart 77, 130-132 (1997).
86. S. Morner, P. Richard, E. Kazzam, B. Hainque, K. Schwartz, and A. Waldenstrom, Deletion in the cardiac troponin I gene in a family from northern Sweden with hypertrophic cardiomyopathy, J. Mol. Cell Cardiol. 32(3), 521-525 (2000).
87. S. Morner, P. Richard, E. Kazzam, U. Hellman, B. Hainque, K. Schwartz, and A. Waldenstrom, Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden, J. Mol. Cell. Cardiol. 35, 841-849 (2003).
88. H. Kokado, M. Shimizu, H. Yoshio, H. Ino, K. Okeie, Y. Emoto, T. Matsuyama, M. Yamaguchi, T. Yasuda, N. Fujino, H. Ito, and H. Mabuchi, Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene, Circulation 102(6), 663-669 (2000).
89. J. Erdmann, S. Daehmlow, S. Wischke, M. Senyuva, U. Werner, J. Raible, N. Tanis, S. Dyachenko, M. Hummel, R. Hetzer, and V. Regitz-Zagrosek, Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy, Clin. Genet. 64(4), 339-349 (2003).
90. S. L. Van Driest, E. G. Ellsworth, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman, Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy, Circulation 108, 445-451 (2003).
91. F. Torricelli, F. Girolami, I. Olivotto, I. Passerini, S. Frusconi, D. Vargiu, P. Richard, and F. Cecchi, Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in Tuscany, Am. J. Cardiol. 92, 1358-1362 (2003).
92. M. J. Ackerman, S. L. VanDriest, S. R. Ommen, M. L. Will, R. A. Nishimura, A. J. Tajik, and B. J. Gersh, Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective, J. Am. Coll. Cardiol. 39, 2042-2048 (2002).
93. D. S. Van, M. J. Ackerman, S. R. Ommen, R. Shakur, M. L. Will, R. A. Nishimura, A. J. Tajik, and B. J. Gersh, Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy, Circulation 106(24), 3085-3090 (2002).
94. O. Havndrup, H. Bundgaard, P. S. Andersen, L. A. Larsen, J. Vuust, K. Kjeldsen, and M. Christiansen, The Val606Met mutation in the cardiac beta-myosin heavy chain gene in patients with familial hypertrophic cardiomyopathy is associated with a high risk of sudden death at young age, Am. J. Cardiol. 87, 1315-1317 (2001).
95. J. Zhang, A. Kumar, H. J. Stalker, G. Virdi, V. J. Ferrans, K. Horiba, F. J. Fricker, and M. R. Wallace, Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy, Clin. Genet. 59, 248-256 (2001).
96. E. Arbustini, P. Morbini, M. Grasso, R. Fasani, L. Verga, O. Bellini, B. Dal Bello, C. Campana, G. Piccolo, O. Febo, C. Opasich, A. Gavazzi, and V. J. Ferrans, Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits, J. Am. Coll. Cardiol. 31, 645-653 (1998).
97. Y. Miyamoto, H. Akita, N. Shiga, E. Takai, C. Iwai, K. Mizutani, H. Kawai, A. Takarada, and M. Yokoyama, Frequency and clinical characteristics of dilated cardiomyopathy caused by desmin gene mutation in a Japanese population, Eur. Heart J. 22, 2284-2289 (2001).
98. A. Kaminska, S. V. Strelkov, B. Goudeau, M. Olive, A. Dagvadorj, A. Fidzianska, M. Simon-Casteras, A. Shatunov, M. C. Dalakas, I. Ferrer, H. Kwiecinski, P. Vicart, and L. G. Goldfarb, Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cardioskeletal myopathy, Hum. Genet. 114, 306-313 (2004).
99. S. Feld, and A. Caspi, Familial cardiomyopathy with variable hypertrophic and restrictive features and common HLA haplotype, Isr. J. Med. Sci. 28, 277-280 (1992).
100. J. Mogensen, T. Kubo, M. Duque, W. Uribe, A. Shaw, R. Murphy, J. R. Gimeno, P. Elliott, and W. J. McKenna, Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations, J. Clin. Invest. 111, 209-216 (2003).
101. M. K. Baig, J. H. Goldman, A. L. Caforio, A. S. Coonar, P. J. Keeling, and W. J. McKenna, Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease, J. Am. Coll. Cardiol. 31, 195-201 (1897).
102. B. M. Mayosi, S. Khogali, B. Zhang, and H. Watkins, Cardiac and skeletal actin gene mutations are not a common cause of dilated cardiomyopathy [letter], J. Med. Genet. 36, 796-797 (1999).
103. S. Karkkainen, K. Peuhkurinen, P. Jaaskelainen, R. Miettinen, P. Karkkainen, J. Kuusisto, and M. Laakso, No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy, Am. Heart J. 143(6), E6 (2002).
104. E. Takai, H. Akita, N. Shiga, K. Kanazawa, S. Yamada, M. Terashima, Y. Matsuda, C. Iwai, K. Kawai, Y. Yokota, and M. Yokoyama, Mutational analysis of the cardiac actin gene in familial and sporadic dilated cardiomyopathy, Am. J. Med. Genet. 86, 325-327 (1999).
105. B. L. Siu, H. Niimura, J. A. Osborne, D. Fatkin, C. MacRae, S. Solomon, D. W. Benson, J. G. Seidman, and C. E. Seidman, Familial dilated cardiomyopathy locus maps to chromosome 2q31, Circulation 99, 1022-1026 (1897).
106. D. Li, G. Z. Czernuszewicz, O. Gonzalez, T. Tapscott, A. Karibe, J. B. Durand, R. Brugada, R. Hill, J. M. Gregoritch, J. L. Anderson, M. Quinones, L. L. Bachinski, R. Roberts, Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy, Circulation 104(18), 2188-2193 (2001).
107. E. L. Hanson, P. M. Jakobs, H. Keegan, K. Coates, S. Bousman, N. H. Dienel, M. Litt, and R. E. Hershberger, Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy, J. Card. Fail. 8(1), 28-32 (2002).
108. P. Ray, H. Pimenta, R. Paulmurugan, F. Berger, M. E. Phelps, M. Iyer, and S. S. Gambhir, Noninvasive quantitative imaging of protein-protein interactions in living subjects, Proc. Natl. Acad. Sci. USA 99, 3105-3110 (2002).